Matt Hewitt
Stock Analyst at Craig-Hallum
(2.99)
# 1,088
Out of 4,641 analysts
41
Total ratings
38.71%
Success rate
3.86%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology | Upgrades: Buy | $6 | $4.37 | +37.30% | 2 | Sep 12, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $23 → $30 | $22.61 | +32.68% | 3 | Aug 12, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $106.50 | +31.46% | 3 | Jul 9, 2024 | |
| SLP Simulations Plus | Reiterates: Buy | $56 | $34.25 | +63.50% | 7 | Jul 3, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.76 | +468.18% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $18.68 | +60.60% | 3 | May 2, 2024 | |
| CDMO Avid Bioservices | Maintains: Buy | $22 → $16 | $10.43 | +53.40% | 4 | Dec 8, 2023 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $3.84 | +82.29% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $144.14 | +38.75% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $4.04 | +147.52% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $9.01 | +232.96% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $4.67 | +8,465.31% | 1 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $170 → $205 | $41.10 | +398.78% | 5 | Nov 3, 2021 |
Champions Oncology
Sep 12, 2024
Upgrades: Buy
Price Target: $6
Current: $4.37
Upside: +37.30%
BioLife Solutions
Aug 12, 2024
Maintains: Buy
Price Target: $23 → $30
Current: $22.61
Upside: +32.68%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $106.50
Upside: +31.46%
Simulations Plus
Jul 3, 2024
Reiterates: Buy
Price Target: $56
Current: $34.25
Upside: +63.50%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.76
Upside: +468.18%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $18.68
Upside: +60.60%
Avid Bioservices
Dec 8, 2023
Maintains: Buy
Price Target: $22 → $16
Current: $10.43
Upside: +53.40%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $3.84
Upside: +82.29%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $144.14
Upside: +38.75%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $4.04
Upside: +147.52%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $9.01
Upside: +232.96%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $4.67
Upside: +8,465.31%
Nov 3, 2021
Maintains: Buy
Price Target: $170 → $205
Current: $41.10
Upside: +398.78%